Commentary Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/AIDS.3.016
Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV
Francesca Macaluso1, Deborah R. Gustafson2,*
- 1Department of Medicine, State University of New York at Downstate Health Sciences University, Brooklyn NY, United States
- 2Professor, Department of Neurology, Section for NeuroEpidemiology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA
Corresponding Author
Deborah R. Gustafson, deborah.gustafson@downstate.edu
Received Date: February 04, 2021
Accepted Date: March 26, 2021
Macaluso F, Gustafson DR. Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV. J AIDS HIV Treat. 2021; 3(2): 21-23.
Copyright: © 2021 Macaluso F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Body Mass Index and Treatment Response in Patients with Cardiac Light-Chain Amyloidosis
Elevated body mass index (BMI) has been associated with an increased risk of cancer and has been shown to have a negative impact on survival in patients with breast, prostate, oral cancer, and leukemia. In plasma cell dyscrasias, obesity has not only been shown to be a risk factor for the development of multiple myeloma, but also has been associated with a higher rate of progression from monoclonal gammopathy of unknown significance (MGUS) to multiple myeloma, and if intervened on, has bee
Tenofovir at the Crossroad of the Therapy and Prophylaxis of HIV and HBV Infections
Tenofovir, alias (R)-PMPA, was first divulged as an anti- HIV agent in 1993 [1]. That it would in 2012, become the first antiretroviral agent, approved by the US FDA (Food and Drug Administration) to prevent HIV infection, could have been predicted from the findings of Tsai et al.
Older Versus Younger Men Who Have Sex with Men: Awareness of and Potential Barriers to the Use of Pre-Exposure Prophylaxis (PrEP) Medication to Prevent the Transmission of HIV
Men who have sex with other men (MSM) comprise the single largest group of individuals contracting HIV in the United States, accounting for more than one-half of all new HIV diagnoses.
Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV
Among women living with HIV (WLWH), increases in body weight and body mass index (BMI, kg/m2) have been observed after switching to the antiretroviral therapies (ART) - Integrase Inhibitors (INSTI) and/or Tenofovir Alafenamide (TAF).
Body Mass Index and COVID-19: Likely Causes for Obesity and Undernutrition Correlation with Disease Severity
Very early on clinicians around the world reported that in addition to aging and various heart pathologies, excess of body weight, especially obesity is a major risk factor for the severity of COVID-19 infection. The multitude of symptoms that have been described from human patients likely arises from the broad distribution of ACE2, a member of the angiotensin receptor family, the receptor for SARS-CoV-2, among which adipose tissue is a prominent one.